anti-CD16/anti-CD20 bispecific NK-cell engager (Genmab)

N/A

Report date: 2025/02/01 20:00:06

Base Information

Drug Nameanti-CD16/anti-CD20 bispecific NK-cell engager (Genmab)

Drug Alias NameCD20-directed bispecific NK-cell engager/B-cell depleting antibody (Genmab)[2xCD16] bispecific NK cell engager antibody (Genmab)anti-CD16/anti-CD20 bispecific immune-cell engager (Genmab)

ClassificationBiologics > Protein drugs > Immunoglobulin > Antibody > Monoclonal antibody > Multispecific monoclonal antibody > Bispecific monoclonal antibody

Mechanisms of ActionLow affinity immunoglobulin gamma Fc region receptor III agonistsB-lymphocyte antigen CD20 modulators

TargetsB-lymphocyte antigen CD20Low affinity immunoglobulin gamma Fc region receptor III

Therapy Area/IndicationsLymphoma, B-Cell

Global Approved IndicationsN/A

Approved Indications in ChinaN/A

Original Approved Country/TerritoryN/A

Original Approved DateN/A

Country/TerritoryUnited States

CombinationsNo

Global Highest StatusPending (Preclinical)

Highest Status in ChinaN/A

Originator CompaniesGenmab A/S

China Registration ClassN/A

Develop Information

Active CompaniesN/A

Inactive CompaniesGenmab A/S

Active IndicationsN/A

Inactive IndicationsLymphoma, B-Cell

Other Information

ATC CodeN/A